SynthesisBMC cancer2012
Hepatitis viruses infection and risk of intrahepatic cholangiocarcinoma: evidence from a meta-analysis.
Synthesis in BMC cancer, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 58 papers, 6 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
58 citing papers in PubMed, 6 syntheses or guidelines pooled it.
- Cancers Attributable to Infections in the US in 2017: A Meta-Analysis.JAMA oncology · 2023Pooled it
- Hepatitis B virus and hepatitis C virus play different prognostic roles in intrahepatic cholangiocarcinoma: A meta-analysis.World journal of gastroenterology · 2016Pooled it
- HBV Infection Status and the Risk of Cholangiocarcinoma in Asia: A Meta-Analysis.BioMed research international · 2016Pooled it
- Possible association between hepatitis C virus and malignancies different from hepatocellular carcinoma: A systematic review.World journal of gastroenterology · 2015Pooled it
- Cholelithiasis and the risk of intrahepatic cholangiocarcinoma: a meta-analysis of observational studies.BMC cancer · 2015Pooled it
- Hepatitis C virus infection and the risk of intrahepatic cholangiocarcinoma and extrahepatic cholangiocarcinoma: evidence from a systematic review and meta-analysis of 16 case-control studies.World journal of surgical oncology · 2015Pooled it
- Pemigatinib in previously treated Chinese patients with locally advanced or metastatic cholangiocarcinoma carrying FGFR2 fusions or rearrangements: A phase II study.Cancer medicine · 2023Trial
- Long-term risk of primary liver cancers in entecavir versus tenofovir treatment for chronic hepatitis B.Scientific reports · 2021Trial
- Survival and Recurrence in Liver Transplant Patients With Intrahepatic Cholangiocarcinoma and Hepatocellular Carcinoma.Annals of transplantation · 2026Article
- Long-Term Outcomes of Combined Hepatocellular Carcinoma-Cholangiocarcinoma After Liver Transplantation in Patients with or without Concurrent Hepatocellular Carcinoma.Annals of transplantation · 2025Article
- Identifying risk factors of biliary tract cancers using a large Japanese regional insurance claims database.Scientific reports · 2025Article
- Factors Contributing to the High Malignancy Level of Cholangiocarcinoma and Its Epidemiology: Literature Review and Data.Biology · 2025Review
- Rare Case of Undifferentiated Embryonal Sarcoma of the Liver that Contained an Adenocarcinoma Component.Surgical case reports · 2025Article
- Impact of Clinical Characteristics and Treatment on Cholangiocarcinoma Prognosis in Southern Thailand.Cancer medicine · 2024Article
- Review
- Cholangiocarcinoma: Recent Advances in Molecular Pathobiology and Therapeutic Approaches.Cancers · 2024Review
- A Call To Action: Cholangiocarcinoma in the Setting of Sustained Hepatitis C Virologic Response - Case Report and Review of Literature.Journal of community hospital internal medicine perspectives · 2023Article
- Analysis of viral integration reveals new insights of oncogenic mechanism in HBV-infected intrahepatic cholangiocarcinoma and combined hepatocellular-cholangiocarcinoma.Hepatology international · 2022Article
- Cholangiocellular carcinoma occurrence after HCV eradication therapy: case series and review of the literature.Journal of medicine and life · 2022Review
- Hepatitis B and C virus infections and the risk of biliary tract cancers: a meta-analysis of observational studies.Infectious agents and cancer · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundStudies investigating the association between Hepatitis B virus (HBV) and hepatitis C virus (HCV) infections and intrahepatic cholangiocarcinoma (ICC) have reported inconsistent findings. We conducted a meta-analysis of epidemiological studies to explore this relationship.
methodsA comprehensive search was conducted to identify the eligible studies of hepatitis infections and ICC risk up to September 2011. Summary odds ratios (OR) with their 95% confidence intervals (95% CI) were calculated with random-effects models using Review Manager version 5.0.
resultsThirteen case-control studies and 3 cohort studies were included in the final analysis. The combined risk estimate of all studies showed statistically significant increased risk of ICC incidence with HBV and HCV infection (OR = 3.17, 95% CI, 1.88-5.34, and OR = 3.42, 95% CI, 1.96-5.99, respectively). For case-control studies alone, the combined OR of infection with HBV and HCV were 2.86 (95% CI, 1.60-5.11) and 3.63 (95% CI, 1.86-7.05), respectively, and for cohort studies alone, the OR of HBV and HCV infection were 5.39 (95% CI, 2.34-12.44) and 2.60 (95% CI, 1.36-4.97), respectively.
conclusionsThis study suggests that both HBV and HCV infection are associated with an increased risk of ICC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.